Sugi Predict

Sugi Predict / Compounds / SCHEMBL3182745

SCHEMBL3182745

SCHEMBL3182745

COC(=O)[C@@H]1C[C@@H](OS(=O)(=O)c2ccc(C)cc2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.47
▸ NR1H3 Q13133 1/20 0.47
▸ MCL1 Q07820 9/20 0.45
▸ MMP2 P08253 2/20 0.44
▸ ANPEP P15144 2/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ CYP3A4 P08684 3/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ PTPN1 P18031 1/20 0.42
▸ CYP2D6 P10635 1/20 0.41
▸ HSD11B1 P28845 1/20 0.41
▸ P2RX3 P56373 1/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ BCL2 P10415 1/20 0.39
▸ BCL2L1 Q07817 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8166919 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL6847613 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL2819569 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL6847935 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL4320166 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL25097911 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL6847610 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL3187965 0.94 MCL1 (0.44) NR1H2NR1H3MCL1KMT2ACYP3A4
SCHEMBL30148070 0.94 MCL1 (0.44) NR1H2NR1H3MCL1KMT2ACYP3A4
SCHEMBL13481726 0.94 MCL1 (0.44) NR1H2NR1H3MCL1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12390446-B2 Proline-based neuropeptide FF receptor modulators RESEARCH TRIANGLE INSTITUTE (US) 2025-08-19 — — US disclosed
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2025-04-10 — — US disclosed
EP-4384520-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 — — EP disclosed
EP-3583096-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2024-03-27 — — EP disclosed
US-20240058303-A1 PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS RES TRIANGLE INST (US) 2024-02-22 — — US disclosed
EP-3490994-B1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2024-02-07 — — EP disclosed
US-11826350-B2 Proline-based neuropeptide FF receptor modulators RESEARCH TRIANGLE INSTITUTE (US) 2023-11-28 — — US disclosed
US-20230348462-A1 IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2023-11-02 — — US disclosed
EP-4240741-A1 IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS Deutsches Krebsforschungszentrum (DE) 2023-09-13 — — EP disclosed
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2023-07-25 — — US disclosed
EP-0618810-B1 BRADYKININ ANTAGONIST PEPTIDES SCIOS NOVA INC (US) 2001-07-04 — — EP disclosed
WO-2000001714-A1 EFFLUX PUMP INHIBITORS MICROCIDE PHARMACEUTICALS, INC. (US) 2000-01-13 — — WO disclosed
EP-0618809-B1 BRADYKININ TYPE PEPTIDES SCIOS NOVA INC (US) 1998-08-19 — — EP disclosed
US-5385889-A Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist SCIOS NOVA INC. (US) 1995-01-31 — — US disclosed
EP-0618810-A4 BRADYKININ ANTAGONIST PEPTIDES. SCIOS NOVA INC (US) 1994-12-07 — — EP disclosed
EP-0618809-A1 BRADYKININ TYPE PEPTIDES SCIOS NOVA INC. (US) 1994-10-12 — — EP disclosed
EP-0618810-A1 BRADYKININ ANTAGONIST PEPTIDES SCIOS NOVA INC. (US) 1994-10-12 — — EP disclosed
EP-0618809-A4 BRADYKININ TYPE PEPTIDES. SCIOS NOVA INC (US) 1994-07-28 — — EP disclosed
WO-1992018155-A1 BRADYKININ TYPE PEPTIDES NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) 1992-10-29 — — WO disclosed
WO-1992018156-A1 BRADYKININ ANTAGONIST PEPTIDES NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) 1992-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348462-A1 IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS ATM, CHEK2, CHEK1 NR1H2 2104/4885NR1H3 2301/4885MCL1 692/4885
US-12390446-B2 Proline-based neuropeptide FF receptor modulators NPFFR1, NPFFR2, NPBWR1 NR1H2 1371/4885NR1H3 1600/4885MCL1 4580/4885
US-11826350-B2 Proline-based neuropeptide FF receptor modulators NPFFR1, NPFFR2, NPBWR1 NR1H2 1371/4885NR1H3 1600/4885MCL1 4580/4885
US-20240058303-A1 PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS NPFFR1, NPFFR2, NPBWR1 NR1H2 1371/4885NR1H3 1600/4885MCL1 4580/4885
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 NR1H2 2448/4885NR1H3 2520/4885MCL1 37/4885
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease CCNE2, CCNE1, CCNT1 NR1H2 135/4885NR1H3 121/4885MCL1 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.